Background

The Foreign-Trade Zones Board has recently announced the actions listed below. For more information on how FTZs can benefit your business, please contact attorney Lenny Feldman at (305) 894-1011 or via email.

- received an application for subzone status for the All Ways Pacific LLC facility within FTZ 44 in Dayton, N.J. (comments due by April 19)

- received a notification of proposed production activity at the M.M.O. Companies Inc. facilities within FTZ 31 in Mascoutah and Edwardsville, Ill., which are used for the disassembly of firearms and ammunition as well as the modification of receivers (comments due by April 19)

- received a notification of proposed production activity at the Liebel-Flarsheim Company LLC facility within FTZ 93 in Raleigh, N.C., which is used for the production of diagnostic imaging contrast media (comments due by April 19)

- received a notification of proposed production activity at the Merck & Co. Inc. facility within FTZ 185 in Elkton, Va., where Merck already has authority to produce pharmaceutical products, to add a finished product and foreign-status materials to the scope of authority (comments due by April 19)

- received an application for subzone status for the Piramal Critical Care Inc. facility within FTZ 44 in Linden, N.J. (comments due by April 19)

- received an application for subzone status at the Pepper+Fuchs Inc. facility within FTZ 84 in Katy, Texas (comments due by April 21)

- approved the establishment of subzone 221B at the CMC Steel Fabricators Inc. facility in Mesa, Ariz.

Copyright © 2024 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.

Practice Areas

ST&R: International Trade Law & Policy

Since 1977, we have set the standard for international trade lawyers and consultants, providing comprehensive and effective customs, import and export services to clients worldwide.

View Our Services 

Close

Cookie Consent

We have updated our Privacy Policy relating to our use of cookies on our website and the sharing of information. By continuing to use our website or subscribe to our publications, you agree to the Privacy Policy and Terms & Conditions.